tiprankstipranks
Advertisement
Advertisement

VIR Stock Latest News

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
The FlyMirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
12h ago
VIR
MIRM
Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley
PremiumThe Fly
Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley
12h ago
VIR
MIRM
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair
PremiumCompany Announcements
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair
1d ago
8K
VIR
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
PremiumRatings
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
11d ago
VIR
Vir Biotechnology Announces Board Changes and Shareholder Approvals
PremiumCompany Announcements
Vir Biotechnology Announces Board Changes and Shareholder Approvals
14d ago
8K
VIR
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
PremiumThe FlyVir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
24d ago
VIR
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
Premium
The Fly
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
1M ago
VIR
Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
Premium
Ratings
Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
1M ago
VIR
Vir Biotechnology Signals Momentum in Latest Earnings Call
PremiumCompany Announcements
Vir Biotechnology Signals Momentum in Latest Earnings Call
1M ago
VIR
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
PremiumRatings
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
1M ago
VIR
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
PremiumThe Fly
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
1M ago
VIR
Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target
PremiumRatings
Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target
1M ago
VIR
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update
PremiumCompany AnnouncementsVir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update
2M ago
VIR
Vir Biotechnology closes global collaboration agreement with Astellas Pharma
Premium
The Fly
Vir Biotechnology closes global collaboration agreement with Astellas Pharma
2M ago
SNY
VIR
Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500
Premium
The Fly
Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500
2M ago
VIR
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition
PremiumCompany Announcements
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition
2M ago
8K
VIR
Vir Biotechnology Names CEO Marianne De Backer as President
PremiumCompany Announcements
Vir Biotechnology Names CEO Marianne De Backer as President
3M ago
8K
VIR
Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright
PremiumThe Fly
Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright
3M ago
VIR
Vir Biotechnology Raises Capital Through Public Stock Offering
PremiumCompany Announcements
Vir Biotechnology Raises Capital Through Public Stock Offering
3M ago
8K
VIR
Vir Biotechnology Announces Significant Common Stock Offering
PremiumCompany AnnouncementsVir Biotechnology Announces Significant Common Stock Offering
3M ago
8K
VIR
Vir Biotechnology 17.65M share Secondary priced at $8.50
Premium
The Fly
Vir Biotechnology 17.65M share Secondary priced at $8.50
4M ago
VIR
TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
Premium
Market News
TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
4M ago
COF
VIR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >